Immix Biopharma, Inc. — Director's Dealing 2025

Jun 23, 2025

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Immix Biopharma, Inc. (IMMX)
CIK: 0001873835
Period of Report: 2025-06-20

Reporting Person: Adams Helen C. (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2025-06-20	Stock Option (Right to Buy)	$2.24	A	33000	Acquired	2035-06-20	Common Stock (33000)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	174754	Direct

Footnotes

F1: The Stock Option will vest in twelve (12) equal monthly installments following the date of grant, subject to the Reporting Person's continued service on the Board of Directors.